All In Biotech

Drug Trial Radar · NCT06902376

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jun 3, 2025

Primary completion

Mar 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals; Exelixis
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).

Conditions

  • Anaplastic Thyroid Cancer
  • Thyroid Cancer
  • BRAF Mutation-Related Tumors

Interventions

  • CemiplimabBiological

    Cemiplimab will be administered at a dose of 350mg intravenous over 30 minutes every 3 weeks for 3 cycles (cycle length is 21 days) at weeks 1, 4, and 7.

  • XL092Drug

    XL092 will be administered at a dose of 60mg PO daily for 8 weeks (weeks 1-8)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete gross resectionTime frame: 12 weeks
  2. Non-hematologic treatment related adverse events (TRAEs)Time frame: Up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dana Farber/Harvard Cancer Center

    Boston, Massachusetts · Not yet recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.